GlassScriptPhysician profile
Molly Mccarthy Walsh
NPI 1891875985
$1,520.96
in general payments reported to CMS, 2019-2025
11 companies · $436 in 2025
The $436 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $30.11 · 2022: $141 · 2023: $504 · 2024: $410 · 2025: $436.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,349.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $473.19 | 2022-2025 | Durysta, Xen Glaucoma Treatment System |
| Bausch & Lomb Americas INC. | $250.00 | 2023-2024 | Infuse |
| Glaukos Corporation | $172.19 | 2025 | Istent Infinite, Idosetr |
| Sight Sciences, INC. | $164.20 | 2024 | Omni Surgical System |
| Mallinckrodt Hospital Products INC. | $156.67 | 2021-2024 | Acthar |
| Regeneron Healthcare Solutions, INC. | $125.00 | 2023 | Eylea Hd |
| Alcon Vision LLC | $99.34 | 2025 | Unity, Clareon, Rocklatan |
| Ocular Therapeutix, INC. | $29.04 | 2025 | Dextenza |
| Horizon Therapeutics Plc | $19.42 | 2023 | Tepezza |
| Allergan, INC. | $16.02 | 2021 | |
| Vantage Technology LLC | $15.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Molly Walsh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.